On the stock market since 1999, it operates in the world of health and science. It has 17,818 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The gap is $2.8B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 23% below its peak. The market has trimmed its expectations for the company.
It pays out $0.78 per share each year — regular cash for whoever holds the stock.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, SNN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SNN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.